Clinical efficacy of and switch from T helper 2 to T helper 1 cytokine profile after interferon alpha2a monotherapy for human echinococcosis.
Harraga
S
S
WHO Collaborating Center on Prevention and Treatment of Human Echinococcosis, Faculté de Médecine et de Pharmacie, Université de Franche-Comté, Besançon, France.
Godot
V
V
Bresson-Hadni
S
S
Pater
C
C
Beurton
I
I
Bartholomot
B
B
Vuitton
D A
DA
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D016207:Cytokines / Q000097:blood*; D004444:Echinococcosis, Hepatic / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000276:immunology*; D006526:Hepatitis C / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000097:blood; D016753:Interleukin-10 / Q000097:blood; D015847:Interleukin-4 / Q000097:blood; D015848:Interleukin-5 / Q000097:blood; D011994:Recombinant Proteins; D018417:Th1 Cells / Q000276:immunology*; D018418:Th2 Cells / Q000276:immunology*
D000998:Antiviral Agents; D016207:Cytokines; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D015848:Interleukin-5; D011994:Recombinant Proteins; D016753:Interleukin-10; D015847:Interleukin-4; D007371:Interferon-gamma